PT  - JOURNAL ARTICLE
AU  - Djoumessi, Kerol
AU  - Huang, Ziwei
AU  - Kühlewein, Laura
AU  - Rickmann, Annekatrin
AU  - Simon, Natalia
AU  - Koch, Lisa M.
AU  - Berens, Philipp
TI  - An Inherently Interpretable AI model improves Screening Speed and Accuracy for Early Diabetic Retinopathy
AID  - 10.1101/2024.06.27.24309574
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.27.24309574
4099  - http://medrxiv.org/content/early/2024/06/27/2024.06.27.24309574.short
4100  - http://medrxiv.org/content/early/2024/06/27/2024.06.27.24309574.full
AB  - Background Diabetic retinopathy (DR) is a frequent concomitant disease of diabetes, affecting millions worldwide. Screening for this disease based on fundus images has been one of the first successful use cases for modern artificial intelligence in medicine. Current state-of-the-art systems typically use black-box models to make referral decisions, requiring post-hoc methods for AI-human interaction.Methods In this retrospective reader study, we evaluated an inherently interpretable deep learning model, which explicitly models the local evidence of DR as part of its network architecture, for early DR screening. We trained the network on 34,350 high-quality fundus images from a publicly available dataset and validated its state-of-the-art performance on a large range of ten external datasets. We obtained detailed lesion annotations from ophthalmologists on 65 images to study if the class evidence maps highlight clinically relevant information. Finally, we tested the clinical usefulness of our model in a reader study, where we compared screening for DR without AI support to screening with AI support with and without AI explanations.Results The inherently interpretable deep learning model obtained an accuracy of .906 [.900-.913] (95%-confidence interval) and an AUC of .904 [.894 – .913] on the internal test set and similar performance on external datasets. High evidence regions directly extracted from the model contained clinically relevant lesions such as microaneurysms or hemorrhages with a high precision of .960 [.941 - .976]. Decision support by the model highlighting high-evidence regions in the image improved screening accuracy for difficult decisions and improved screening speed.Interpretation Inherently interpretable deep learning models can reach state-of-the-art performance and support screening for early DR by improving human-AI collaboration.Funding This work was supported by the Hertie Foundation, the German Science Foundation (BE5601/8-1 and the Excellence Cluster 2064 “Machine Learning — New Perspectives for Science”, project number 390727645), the Carl Zeiss Foundation (“Certification and Foundations of Safe Machine Learning Systems in Healthcare”) and International Max Planck Research School for Intelligent Systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Hertie Foundation, the German Science Foundation (BE5601/8-1 and the Excellence Cluster 2064 Machine Learning - New Perspectives for Science, project number 390727645), the Carl Zeiss Foundation (Certification and Foundations of Safe Machine Learning Systems in Healthcare) and International Max Planck Research School for Intelligent Systems (IMPRS-IS) for supporting KD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data. The main development dataset was originally located at https://kaggle.com/competitions/diabetic-retinopathy-detection. All datasets are described in detail in Table 1 and references 20-29.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online.https://github.com/berenslab/retimgtools/releases/tag/v1.1.0 https://github.com/kdjoumessi/Sparse-BagNet_clinical-validation